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1. Introduction 
Nowadays, there is still no gold standard test for Inflammatory Bowel Disease (IBD). Many 
etiologies are responsible of an inflammation of the gut. When a patient presents with signs 
suggestive of IBD (abdominal pain, diarrhea, and sometimes fever), the clinician had to 
establish whether the patient suffers from an IBD or from one of the numerous alternative 
diseases. The use of immunosuppressive agents and biotherapies in IBD treatment enforces 
the necessity to distinguish them from infectious diseases, particularly from tuberculosis. 
Clinical signs of IBD are not specific. This review will focus on the differential diagnosis of 
Crohn’s Disease (CD) and on the helpful tests for the diagnosis. Histopathological findings 
are sometimes insufficient to establish the diagnosis, granuloma is not specific and 
inconstant in CD (only in 15 to 60 % of cases). Serological assays (perinuclear antineutrophil 
antibodies pANCA and anti-Saccharomyces cerevisae antibodies ASCA) are contributing to 
the diagnosis, but their sensitivity and specificity are too weak for a gold standard. This 
review will be divided in 2 parts: first, a review of etiologies inducing granulomas in the gut 
(infections, systemic diseases, drug related disorder…), second, a review of controversies in 
the distinction between ulcerative colitis (UC) and CD. This review will contribute to 
provide to clinicians a strategy for differential diagnosis of CD (infection, systemic disease, 
neoplasm, drug related disorders, non specific inflammation…). Therefore, sensible and 
specific biomarkers are needed to facilitate the diagnosis of IBD in the future.  
Crohn’s disease is an Inflammatory Bowel Disease (IBD), able to affect all the gut mucosa. 
Crohn disease may induce lesion of epithelioid granuloma. However, this type of lesion 
may be associated with others affections, certain of these affections are infectious diseases, 
and contra-indicate formally the immunotherapy. Nowadays, there is no gold standard 
assay to make the etiological diagnosis of granuloma of the gastrointestinal (GI) tract.  
2. How differentiate CD from tuberculosis? 
The differential diagnosis of CD and tuberculosis of the digestive tract is challenging, as the 
incidence of CD is dramatically increasing in countries where TB is too prevalent, and as TB 
epidemic restarts in the developed countries. Since the presence of a caseation necrosis in 
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endoscopic biopsies confirms TB, this histological findings stay uncommon in the most cases 
of digestive TB. Surgical biopsies are more efficient to establish the diagnosis of TB (1). A 
confusion between TB and CD is not Exceptional. In a saoudian  study, 21% of the patients 
treated for a digestive TB, were really affected by CD (2). Clinically, the differential 
diagnosis is uneasy. Digestive TB is induced by hematogenous spread after the inhalation of 
the bacillus or by ingestion of mycobacterium bovis. In case of an infection by mycobacterium 
tuberculosis, the association with a pulmonary TB is unconsistent. Certain localizations for 
lesion are more frequent in TB than in CD. Preponderant localizations are presented in table 
1. After a comparison between 53 patients with CD and 53 others with digestive TB, 
Makharia et al. establish a clinical, endoscopic et histological score to differentiate TB (3). In 
this study, chronic diarrhea, blood in the stools, perianal disease and extraintestinal 
manifestations were significantly more frequent in CD than in TB. On the other side, 
abdominal pain, constipation, intestinal obstruction, loss of appetite, and weight loss were 
associated with TB. Sites of CD involvement were more often rectum, sigmoid, ascending 
and descending colon. The type of lesions in endoscopy was also different in the two 
groups: skip lesions, friability, aphtous, linear and superficial ulcers, and cobblestoning 
were more often observed in the CD group. Nodular lesions were more frequent in the TB 
group. Histological examination found more and larger granulomas per section in TB, and 
more often lesion of focally enhanced colitis in CD. The developed score is: -2,5*Involvement 
of sigmoïd colon-2,1* blood in stool+2,3*weight loss-2,1*focally enhanced colitis+7 where 
each characteristics were given 1 if present and 0 if absent. With a cutt-off of 5,1, this score 
demonstrated a good sensibility, a good specificity and a good ability to correctly classify 
the two diseases. The area under the receiver operating curve (AUC-ROC) was 89,2. 
Endoscopic examination is really helpful to differentiate TB from CD. Considering that 
anorectal lesions, longitudinal ulcers, aphtous ulcers cobblestone appearance were typical in 
CD, and that involvement of fewer than four segments, a patulous ileocecal valve, 
transverse ulcers, and scars of pseudopolypes were typical of intestinal TB, Lee et al. 
hypothesized that CD diagnostic could be made when the number of parameters 
characteristic of CD was greater than parameters associated with TB (4). With these 
assumptions, diagnosis was correctly made in 87,5 % of the patients. Histological 
examination is also useful. However, characteristic lesions of TB as confluent granulomas, 
more than 10 granulomas per biopsy sites, and caseous necrosis are present in only a limited 
number of TB cases (50%, 33%, 22% respectively)(5). Mycobacterium is found by direct 
examination of biopsy in only 20 to 50% of intestinal TB cases.  
 
Crohn’s Disease Tuberculosis 
Rectum 
Sigmoid colon 
Descending colon 
Jejunum 
Ileocecal region 
Ascending colon 
Rectum 
Table 1. Principal localisations of granuloma in CD and TB 
Serological test to differentiate CD and ulcerative colitis (UC) as detection of perinuclear 
anti-neutrophil antibodies (p-ANCA), and anti-saccharomyces cerevisae antibodies (ASCA) 
are not useful to differentiate CD from TB. Several studies had shown that IgA and/or IgG 
level of ASCA was not different between patients with CD and intestinal tuberculosis. P-
ANCA was also similar in patients with CD than in patients with intestinal TB. Nowadays, 
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serological test with p-ANCA & ASCA are not helpful to differentiate TB from CD. 
Intradermoreaction with tuberculin is not enough sensible or enough specific to make the 
diagnosis of intestinal TB, as it can be positive in the case of infections due to others 
Mycobacteriae and after vaccination and negative in immunocompromised patients. 
Quantiferon is a blood test of reactivity of lymphocytes T to TB antigens with production of 
interferon gamma which is not influenced by vaccination. Up today, no study is published 
on the diagnosis value of quantiferon TB for differentiating between TB and CD. There are 
only cases reports about positive quantiferon in case of intestinal TB. However, quantiferon 
is often negative in cases of extrapulmonar TB as osteitis due to Mycobacteria.  
Cultures of Mycobacteria are difficult and long (3 to 8 weeks). Polymerase Chain Reaction 
(PCR) in intestinal biopsy, or in stools might be a good tool. Yet, the sensibility of the PCR 
Mycobacterium tuberculosis varies from 31 to 60% in biopsies (6). A positive PCR was less 
frequent than caseation necrosis, and presence of bacillus after Ziehl and Neelsen staining. 
A PCR positive in stools might help to make the diagnosis of intestinal TB, with a sensibility 
of 79% and a good specificity, however, this PCR may be positive in case of pulmonary TB 
without intestinal involvement (7).  
3. Non tuberculous mycobacteria: Another cause of intestinal granuloma or 
an agent for CD? 
In immuno-compromised patients (particularly HIV-positive subjects and transplanted 
patients), Mycobacterium avium paratuberculosis (MAP) is often incriminated in intestinal 
granulomatous disorders. However, several authors hypothesized that it might be a causal 
agent of CD. Long term blood culture from a great number of CD patients are positive for 
MAP, yet a great proportion of healthy controls exhibit positive blood culture. The 
frequency of MAP positive blood culture is greater in the groups of CD patients (8). 
However, these results are insufficient to conclude that MAP is a causal agent for CD. It 
might be a consequence of a modified commensal microbiota. A defective sensing and 
killing of bacteria (due to mutation in pattern-recognition receptors) might contribute to the 
onset of the disease (9). The only temporary efficacy of anti-tuberculous therapy in patients 
with CD is not in favor of a causal role of MAP in CD (10).  
4. Helicobacter pylori (HP): An under-estimated agent of granulomatous 
gastritis 
HP is a potential agent for granulomatous gastritis. Its frequency might be under-estimated. 
In 18 patients with granulomatous gastritis, HP was found in 14 cases, diagnosis of CD was 
made in only 1 case (11). For others, infection with HP is only concomitant of CD (12).  
5. Gastro-intestinal histoplamosis: A difficult but urgent diagnosis 
Histoplasma capsulatum (HC) is a mold which is common in mid-western USA, and south 
America. The most of patients with a disseminated histoplasmosis exhibits HC in 
gastrointestinal tract. First, HC is inhaled and disseminated in the all organism. Risk factors 
for HC are immunodepression: AIDS, CD4 lymphopenia, immunosuppressive agents. 
Gastrointestinal involvement may occur as a result of the adjacent mediastinal adenitis or 
fibrosing mediastinitis. Clinical manifestations are dysphagia, upper gastrointestinal 
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bleeding, broncho-oesophageal fistula, abdominal pain, weight loss, lower GI bleeding, 
intestinal occlusion in the case of an intestinal involvement. However, GI involvement of 
HC may be asymptomatic. Diagnosis can be made after periodic acid Schiff (PAS) stain, 
antigen detection in blood and urine, serology and cultures are useful to establish the 
diagnosis as they are often positive in patients with histoplasmosis (13). This pathology is 
uncommon, but in the most of cases, no travel in endemic zone is identified. Other 
manifestations can be seen as hyperferritinemia, macrophagic activation syndrome, 
pancytopenia. The presence of these extradigestive manifestations in immunocompromised 
patients may encourage physicians to look for histoplasmosis.  
6. Tropheryma whipplei (TW): A “real” pathogen with frequent asymptomatic 
carriers  
Whipple’s disease is unfrequent. Nine percent of the patients with manifestations of 
Whipple’s disease had duodenal biopsies with granulomatous gastritis without caseation 
necrosis. Clinical manifestations are malabosrption, chronic diarrhea associated with 
arthritis, arthralgia, neurological disorders: supranuclear ophtalmoplegia, cognitive 
disorders. PCR for T. Whipplei is helpful to make the diagnosis. However, as this PCR is 
positive in 1 on 174 healthy patients, the diagnosis is definitive when the PAS staining and 
the PCR are positive, in association with evocating clinical manifestations. Furthermore, this 
PCR is positive in duodenal biopsies in stools of respectively 5 % and 11% of the patients 
with gastric disorders. There are many subjects who are asymptomatic carriers of TW (14).  
7. GI granuloma: Do not forget Syphilis? 
At the secondary and tertiary stage of Treponema Pallidum infection, GI involvement is 
possible with granulomatous lesions (15). Gastric ulcers and upper GI bleeding may be seen. 
Diagnosis is made with serologies TPHA, VDRL, PCR, and immunofluorescence staining in 
biopsies. Differential diagnosis are gastric lymphoma and linitis.  
8. Yersinia: A frequent agent for granulomatous appendicitis 
Yersinia enterolitica and pseudotuberculosis may cause granulomatous appendicitis, ileitis, 
mesenteric adenitis and colitis. The cultures are positive in around 25% of granulomatous 
appendicitis(16). The contamination is due to the ingestion of the bacteria. Some authors 
hypothesized that the defects in mucosal barrier induced by CD favors infection by Yersnia 
(17).  
9. Sarcoïdosis: Rare but not impossible granulomatous involvement of 
digestive tract 
Sarcoïdosis is a systemic granulomatosis, which rarely involves in the gastrointestinal tract 
(almost 3% of the patients). This is a disease, affecting people from 20 to 40 years old; the 
incidence is more frequent in blacks and north Europeans. Gastric lesions and extrinsic 
compression by mediastinal lymphadenopathy are the most frequent (18). Furthermore, any 
cases were reported of, small bowel polyps and colonic obstruction(19,20). Small bowel 
involvement may cause a real enteropathy. To confirm the diagnostic, physicians needs to 
obtain two biopsies from two different sites positive for giant granuloma without caseum, 
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and after having exluded all the other potential diagnosis. Skin biopsies, lymphadenectomy, 
bronchoscopy with biopsy, 18-fluoro-desoxy-glucose scintigraphy may be useful to confirm 
the diagnosis. The dosage of the angiotensin converting enzyme (ACE) is not really helpful 
as every granuloma are secreting (21), as there is a polymorphism for its gene (22), with 
individuals with low level of ACE, even with sarcoidosis. 
10. Other systemic granulomatous disorders: a more frequent GI involvement 
Wegener’s granulomatosis and Churg-Strauss syndrome affects in 80 % of the cases the GI 
tract. Clinically, patients exhibit abdominal pains, nausea, diarrhea and digestive 
hemorrhage (23). Gastroduodenal ulcers may be found. Granuloma is not always found in 
biopsy. Clinically, asthma is always found in Churg-Strauss syndrome and associated with 
hypereosinophilia. The dosage of antineutrophil cytoplasmic antibodies is interesting for the 
diagnosis as the sensibility is almost 70 to 80 % and a similar specificity (23). Anti-PR3 are 
associated with Wegener’s granulomatosis. 
11. Other anecdotic etiologies  
Gastric lymphoma may represent an alternative diagnosis for a gastric granulomatous 
lesion (12). It is often T cells lymphoma or, lymphoma of the gut associated lymphoid tissue. 
Necrosis could be seen in this situation. In Shapiro’s study, 2 patients on 42- with a gastric 
granuloma- were affected by a lymphoma. They also described in this retrospective study, 
cases of adenocarcinoma of the distal oesophagea. Some toxic agents may cause granuloma; 
yet, digestive involvement is rare. These agents are beryllium, -interferon, BCG therapies 
for bladder cancer, and allopurinol. Taeniasis may be associated with granuloma of GI tract.  
There is a genetic disease, which causes immunodeficiency and systemic granulomatosis. 
Chronic septic granulomatosis is often linked to X-chromosome. Patients are susceptible to 
bacterian and fungal infections; it’s the consequence of a modified NADPH-oxydase in 
macrophages. Granulomatous lesions of GI tract are frequent, particularly in colon(24).  
12. Which strategy adopting when histopathological examination is not 
sufficient to make the diagnosis?  
First line, second and third line, laboratory assays helpful to make a diagnosis are presented 
in table 2, 3 and 4. In many cases, the etiological diagnosis is made with all clinical and 
biological arguments. Finally, when the diagnosis stays difficult, an anti-TB treatment might 
be started and its efficacy might lead physicians to conclude for a diagnosis of TB.  
13. Clinical diagnosis with Crohn’s disease among various forms of intestinal 
inflammation 
These diagnosis depend about the anatomic localization of the process  
Ileitis:  
A variety of conditions may mimic Crohn’s iletis. Table 5 report differential diagnosis of 
ileitis. Some others rare aetiologies can be explain ileitis. Infiltrative diseases (amyloidosis 
and eosinophilic gastroenteritis), lymphoid nodular hyperplasia and radiation enteritis must 
be researched also.  
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Laboratory assays Diagnostic orientation Diagnostic value 
Hemogram Lymphopenia : HIV 
infection, 
immunodespression 
Hypereosinophilia : Churg-
Strauss syndrome 
Inflammatory syndrome in 
all cause of digestive 
granuloma 
No sensibility, No specificity 
C-reactive protein Confirmes inflammation No sensibility, no specificity 
Lactate deshydrogenase May orientate to lymphoma 
if increase 
No sensibility, no specificity 
Creatinine, albumine in 
urine/creatinine ratio 
An associated nephropathy 
may be observed in 
Wegener’s granulomatosis 
and Churg-Strauss 
syndrome 
No specificity 
Tuberculin test Tuberculosis, sarcoidosis if 
asynergy 
No specificity (past 
immunization by BCG), no 
sensibility in 
immunocompromised 
patients 
Chest radiography Tuberculosis Only 30% patients with TB of 
GI tract have a pulmonary 
TB 
Testing for HIV by 
serological assay 
Orientate to opportunistic 
infection : histoplasmosis or 
non tuberculosis mycobacteria 
Sensible and specific for HIV 
testing but only give an 
orientation 
Stools cultures 
Parasitological 
examination of the stools 
Yersinia, parasites Sensible 
Helicobacter pylori culture 
in biopsies, or Hp serology
Hp infection Culture may be negative if 
proton pump inhibitor 
therapy 
 
 
 
Table 2. First line biological examination in patients with evidence of a GI tract granuloma 
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Laboratory assays Diagnostic orientation Diagnostic value 
Quantiferon TB gold Tuberculosis Not evaluated in digestive 
tuberculosis 
Mycobacterium tuberculosis 
PCR in stools and biopsies 
Tuberculosis Not enough sensible in 
biopsies, lack of specificity 
in stools as it may be 
positive in pulmonary TB 
ANCA detection Wegener’s granulomatosis 
and Churg-Strauss 
syndrome 
Ulcerative colitis 
Good sensibility, good 
specificity for these three 
etiologies 
ASCA detection Crohn disease Not specific, may be 
positive in TB 
Angiotensin Converting 
enzyme 
sarcoidosis Not sensible, not specific 
and genetic polymorphism 
18-FDG scintigraphy May guide some deep 
biopsies 
Sensible but not specific 
Chest and abdominal 
tomodensitometry 
Search other sites of 
involvement to orientate 
the diagnosis as infiltrative 
pneumopathy 
Not specific 
Table 3. Second line biological or radiological tests 
 
 
 
 
Laboratory assays Diagnostic orientation Diagnostic value 
Tropheryma Whipplei PCR Whipple’s disease Good sensibility, but often 
positive in asymptomatic 
patients 
Urine and blood antigen 
detection of histoplasmosis, 
serology 
Think to histoplasmosis if the 
patients stayed in endemic 
area, or in 
immunocompromised ones 
 
Angiotensin converting 
enzyme genotyping 
Sarcoidosis to interpret ACE 
levels 
 
Yersinia PCR Yersiniosis Sensible 
 
 
Table 4. Third line biological tests 
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Infection Inflammation gynecologic 
Yersinia enterolitica 
Yersinia pseudotuberculosis 
Mycobacterium tuberculosis 
Mycobacterium avium–
intracellulare 
Typhlitis 
Histoplasma capsulatum 
Salmonella 
Cryptococcosis 
Anisakiasis 
Actinomycosis israelii 
Appendicitis 
Appendiceal abscess 
Cecal diverticulitis 
Pelvic inflammatory 
disease 
Tuboovarian abscess 
Ovarian cyst or tumor 
Endometriosis 
Ovarian torsion 
Ectopic pregnancy 
Neoplasm Drug related Vascular 
Cecal or small bowel (ileal) 
adenocarcinoma 
Lymphoma 
Lymphosarcoma 
Carcinoid tumor 
Metastatic cancer 
Nonsteroidal 
antiinflammatory drug-
related ulcer or stricture 
Ischemic: oral 
contraceptives, ergotamine, 
digoxin, diuretics, 
antihypertensives 
Ischemia 
Vasculitides: polyarteritis 
nodosa, Churg–Strauss 
syndrome, 
Takayasu’s arteritis, 
Wegener’s granulomatosis, 
lymphomatoid 
granulomatosis, giant cell 
arteritis, 
rheumatoid arthritis 
vasculitis, thromboangiitis 
obliterans 
Henoch-Scho¨nlein 
purpura 
Systemic lupus 
erythematosus 
Behçet’s syndrome 
Table 5. Differential diagnosis of ileitis 
Proctitis: 
In addition to ulcerative proctitis, proctitis may also occasionally be the presentation of 
crohn’s disease. The other differential diagnosis are breaf (Table 6). 
Colitis:  
The causes of colitis are legion.  
Numerous infectious agents may cause a transient colitis, but the clinical course of most 
enteric infections is usually complete within 2 weeks of onset. The most important infections 
are: Cytomegalovirus, Shigella, Campylobacter, Clostridium difficile, Salmonella, 
Aeromonas pleisioides, Amebiasis, Enterohemorrhagic E. coli (EHEC), Mycobacterium 
tuberculosis, Yersinia enterocolitica, Schistosomiasis and strongylidosis. Nevertheless, 
others aetiologies must be evocated in function of associated symptoms and patient: 
Ischemic colitis, diverticulitis, microscopic colitis, diversion colitic or radation, Behçet 
disease and sarcoidosis. 
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Infection Others 
Herpes simplex type II 
Neisseria gonorrhoeae 
Syphilis (Treponema pallidum) 
Lymphogranuloma venereum 
Chlamydia trachomatis 
Whipworm infestation 
Prolapse 
Solitary rectal ulcer 
Trauma 
Chemical injury 
Table 6. Differential diagnosis of Crohn’s disease or ulcerative proctitis 
Drug related colitis must be researched: NSAIDs, gold, penicillamine) or toxic like cannabis; 
Some aetiologies are rare and must be evocated after these hypothesis: Chronic 
granulomatous disease, graft-vs-host disease.  
 
 
 
 Ulcerative colitis Crohn’s disease 
Distribution Continuous, symmetric, 
and diffuse, with 
granularity or ulceration 
found in entire involved 
segments; 
Often discontinuous and 
asymmetric with skipped 
segments, normal 
intervening mucosa, 
Rectum Typically involving rectum 
and distributed proximally 
Complete or, more often, 
relative rectal sparing may 
be present 
Mucosal lesions Microulcers more common, 
larger ulcers possible, 
pseudopolyps more 
common 
Aphthous ulcers common 
in early disease; late disease 
notable for ulcers with 
stellate, “rake,” “bear-
claw,” linear or serpiginous 
ulcers; cobblestonin 
Depth of inflammation Mucosal, not transmural 
except in fulminant disease 
Submucosal, mucosal, and 
transmural 
Histology Crypt abscesses and ulcers 
are the defining lesion 
Crypt abscesses may be 
present Ulceration on a 
background of inflamed 
mucosa 
Crypt abscesses may be 
present Ulceration on a 
background of inflamed 
mucosa Hallmark is focally 
enhanced inflammation, 
often on a 
normal background 
Complications Parianal findings not 
prominent 
Parianal lesions (40%), 
strictures, fistulas 
Table 7. Clinical distinctions between ulcerative colitis and Crohn’s disease. 
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When a causative agent is not identified, the issue of sorting out a first presentation of IBD 
from an acute self-limited colitis arises. Such a distinction relies strongly on histologic rather 
than endoscopic findings. Once a diagnosis of IBD has been established, Crohn’s disease 
should be distinguished from ulcerative colitis. 
14. Controversies in the distinction between ulcerative colitis and Crohn’s 
disease 
Many distinctions—clinical, anatomic, histologic—have been drawn between the 2 major 
forms of IBD (Table 7). A gold standard of diagnosis has yet to be attained, however. 
Some clinical distinctions challenged by careful observation. Theorycally, ileum is not 
involved, except as “backwash” ileitis in panulcerative colitis. Conversely, ileum is often 
involved in chron’s disease. Backwash ileitis has long been recognized as a feature of pan-
ulcerative colitis but may yet throw even the experienced diagnostician off the trail if more 
than a few centimeters of ileal inflammation are present. When ileitis in the setting of 
pancolitis is more extensive than this, careful appraisal of the ileocecal valve may be helpful. 
A patulous valve with extensive backwash is more convincing as a feature of ulcerative 
colitis than lengthy ileitis behind a constricted, stenotic valve, more suggestive of Crohn’s 
disease. 
Complications are very frequent in the natural history of Crohn’s disease. The 20-year 
cumulative rate of all complications is more than a population-based cohort (25); CD 
evolution relates to disease location. Small bowel involvement might be complicated at 
diagnosis or during the first years after diagnosis by an abcess or fistula, or by a stricture 
followed by formation of a fistula, whereas colonic disease can remain uncomplicated or 
inflammatory for many years. Stricturing and penetrating lesions can coexist in the same 
individual or even within the same intestinal segment. Conversly, in UC perianal findings 
are not prominent. If fissure or fistula have been present, they shouhd be uncomplicated. 
Strictures are rarely present and are suggestive of adenocarcinoma. Moreover, fistulas are 
not present, except for rare occurrence of rectovaginal fistula. In CD, about 20%-30% of 
patients present with perianal lesions and 15%-20% have or had a fistula (26). Another 
diagnostic criterion challenged by careful observation is the classic observation of 
continuous involvement of colonic mucosa without skip areas in ulcerative colitis. Although 
this distinction is generally true, care must be taken in interpreting the finding of skip areas. 
Topical therapies may lead to a false impression of “rectal sparing,” whereas oral or 
systemic therapies may result in patchy healing, depending on the timing of endoscopy or 
completeness of response (27). Accordingly, the most accurate diagnosis may be made at the 
earliest evaluation, before anatomy and histology have been confounded by treatment.  
Given this limitation, it is not surprising that, in some cases, it will be impossible to 
distinguish between ulcerative colitis and Crohn’s disease, with potential implications for 
prognosis and treatment. Prospective, population-based studies suggest that approximately 
1 in 20 patients with IBD will have a diagnosis of indeterminate colitis (28). Subsequent 
follow-up leads to a firmly established diagnosis of ulcerative colitis in one third of these 
cases, whereas 17% are assigned a diagnosis of Crohn’s disease (29). The clinical value of 
pANCA or ASCA testing in patients presenting with non-specific gastrointestinal symptoms 
is limited because of inadequate sensitivity. Thus tests are infrequently positive in 
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individuals who do not have IBD. With the addition the latest panel of 7 antibodies has 
improved the positive and negative values of serologies. Using all of the serologic markers 
reported for CD, the sensitivity for diagnosing CD is greater than 80% and the positive 
predictive value is over 90% but only when the prevalence of CD is high, 38% (30). ANCA 
positivity has been observed in other colitides, such as eosinophilic and collagenous colitis. 
The specificity of ASCA seems to be higher, but ASCA positivity has been observed in 
patients with Behçet’s disease, primary biliary cirrhosis, autoimmune hepatitis, and celiac 
disease. The cost effectiveness of serologic tests in the sequential diagnostic testing of IBD in 
children has been shown to avoid unnecessary and costly evaluations (31), but it has not 
been confirmed by other studies (32).  
Serologic evaluation of ANCAs and ASCAs could be of help in patients with indeterminate 
colitis (33). In these patients, early knowledge of the exact diagnosis could be of clinical 
importance with regard to therapeutic decisions and prognosis (34). Patients who are 
pANCA positive and ASCA negative are 19 times more likely to have UC, whereas patients 
who are ASCA positive and pANCA negative are 16 times more likely to have CD (35). A 
remarkable finding is that patients who do not have antibodies, to either ASCAs or ANCAs, 
are remaining indeterminate colitis after a mean duration of 9.9 years (33). Further 
refinement of serologic tests and/or the combination of serologic testing with routine 
laboratory and fecal tests testing and noninvasive imaging may offer efficient cost-effective 
screening in the future. 
15. Conclusion 
The increases in incidence and prevalence of IBD over the last 15 years and its emergence in 
developing countries indicate a role of the environment in pathogenesis. Their diagnosis 
may be difficult and are clinical, endoscopic and histologic assessment. The issue remains 
that no gold standard test exists for the diagnosis of IBD. For these reasons, diagnosing 
crohn’s disease and ulcerative colitis continues to be a more than occasional challenge to the 
practicing gastroenterologists. In the time of biotherapies, a casual diagnosis of IBD may 
result in critical errors in management in that incorrect diagnosis may result in 
inappropriate or even contraindicated treatment.  
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